drugset / Trial / NCT05822713

A Comparison of the Efficacy of Amisulpride and Placebo in the Prevention of PONV in Patients at Moderate-to-high Risk of PONV.

NCT05822713

Phase 3 Unknown 516 enrolled Qilu Pharmaceutical (Hainan) Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A comparison of the efficacy of Amisulpride and placebo in the prevention of PONV in patients at moderate-to-high risk of PONV.

Timeline

Start
2023-04-29
Primary completion
2023-08-31
Completion
2023-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Amisulpride Small molecule 5 mg Intravenous

Indications

No indication recorded.